Domenica Lorusso
#162,717
Most Influential Person Now
Researcher
Domenica Lorusso's AcademicInfluence.com Rankings
Domenica Lorussocomputer-science Degrees
Computer Science
#9496
World Rank
#9970
Historical Rank
Computational Linguistics
#2301
World Rank
#2324
Historical Rank
Machine Learning
#4169
World Rank
#4218
Historical Rank
Artificial Intelligence
#4514
World Rank
#4576
Historical Rank
Download Badge
Computer Science
Domenica Lorusso's Degrees
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Domenica Lorusso Influential?
(Suggest an Edit or Addition)Domenica Lorusso's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. (2016) (1582)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. (2019) (923)
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. (2019) (829)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma (2020) (559)
- Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. (2014) (322)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (2019) (287)
- Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. (2008) (266)
- A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study (2006) (255)
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). (2007) (245)
- Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO (2010) (232)
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. (2021) (200)
- Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. (2011) (181)
- Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease (2017) (172)
- A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. (2014) (163)
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. (2022) (157)
- Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. (2015) (136)
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (129)
- Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup (2014) (128)
- Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. (2008) (118)
- Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. (2012) (116)
- Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary (2013) (109)
- Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life – An Italian survey (2017) (99)
- Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors (2014) (99)
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer (2017) (98)
- Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors: A MITO-9 Retrospective Study (2011) (92)
- Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. (2016) (91)
- LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial. (2017) (88)
- Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. (2003) (86)
- Survival with Cemiplimab in Recurrent Cervical Cancer. (2022) (80)
- Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. (2021) (80)
- Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study. (2012) (79)
- Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study. (2017) (75)
- Implementation of laparoscopic approach for type B radical hysterectomy: a comparison with open surgical operations. (2015) (74)
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) (72)
- A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy (2008) (70)
- Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). (2010) (70)
- Role of gemcitabine in ovarian cancer treatment. (2006) (70)
- Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. (2015) (69)
- Stereotactic radiotherapy in recurrent gynecological cancer: a case series. (2009) (67)
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. (2015) (64)
- A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. (2008) (63)
- Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. (2014) (63)
- Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer (2003) (61)
- Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. (2018) (58)
- The Role of Lymphadenectomy in Cervical Cancer Patients: The Significance of the Number and the Status of Lymph Nodes Removed in 526 Cases Treated in a Single Institution (2013) (56)
- Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. (2016) (55)
- Fertility sparing surgery in early stage epithelial ovarian cancer (2014) (55)
- Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures. (2015) (54)
- Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. (2017) (53)
- The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study (2016) (52)
- Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. (2020) (52)
- Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. (2010) (52)
- Review role of topotecan in gynaecological cancers: current indications and perspectives. (2010) (50)
- Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, multi‐centre, prospective audit (2018) (50)
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. (2021) (50)
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). (2016) (50)
- The role of human papillomavirus vaccines in cervical cancer: Prevention and treatment. (2018) (49)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary (2014) (48)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix (2014) (47)
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. (2021) (46)
- Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. (2019) (46)
- Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. (2019) (46)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2012) (44)
- Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. (2019) (43)
- An international multicentre prospective audit of elective rectal cancer surgery; operative approach versus outcome, including transanal total mesorectal excision (TaTME) (2018) (43)
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma (2021) (43)
- Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis. (2016) (42)
- Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19). (2016) (40)
- Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease. (2013) (39)
- Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. (2013) (39)
- Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival. (2005) (39)
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) (2022) (39)
- Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. (2011) (39)
- Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients (2012) (38)
- Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. (2017) (38)
- Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. (2015) (38)
- Trabectedin as a chemotherapy option for patients with BRCA deficiency. (2016) (38)
- Surgical Treatment of Recurrent Endometrial Cancer: Time for a Paradigm Shift (2015) (37)
- Investigational drugs for the treatment of cervical cancer (2017) (37)
- Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? (2015) (37)
- New prophylactics human papilloma virus (HPV) vaccines against cervical cancer (2018) (37)
- Sentinel node mapping using hysteroscopic injection of indocyanine green and laparoscopic near-infrared fluorescence imaging in endometrial cancer staging. (2015) (36)
- Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials (2010) (36)
- Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future (2017) (36)
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. (2022) (36)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2015) (35)
- Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. (2017) (34)
- Laparoscopic Sentinel Node Mapping in Endometrial Cancer After Hysteroscopic Injection of Indocyanine Green. (2017) (34)
- A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group (2007) (33)
- Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer (2000) (33)
- Fertility-Sparing Surgery in Early-Stage Cervical Cancer Patients: Oncologic and Reproductive Outcomes (2014) (33)
- The Role of Secondary Surgery in Recurrent Ovarian Cancer (2012) (32)
- Sentinel node mapping in endometrial cancer following Hysteroscopic injection of tracers: A single center evaluation over 200 cases. (2017) (32)
- Emerging drugs for ovarian cancer (2010) (32)
- Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. (2007) (32)
- Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. (2013) (32)
- Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial (2008) (32)
- Uterine serous carcinoma. (2021) (31)
- Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives (2021) (31)
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. (2022) (31)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. (2017) (31)
- FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC) (2019) (31)
- Pegylated liposomal doxorubicin in the management of ovarian cancer (2010) (31)
- European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer. (2021) (29)
- VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma (2021) (28)
- Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery. (2017) (28)
- First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion (2020) (27)
- Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity (2009) (27)
- Morcellation of undiagnosed uterine sarcoma: A critical review. (2016) (27)
- ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. (2021) (27)
- Surgical Management and Prognostic Factors of Vulvovaginal Melanoma (2016) (26)
- Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience (2019) (26)
- Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi‐centre prospective audit (2018) (26)
- Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial. (2020) (25)
- Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery (2018) (25)
- Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients (2004) (25)
- Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study (2008) (25)
- Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. (2021) (25)
- Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial. (2021) (24)
- Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. (2017) (24)
- Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study (2011) (24)
- Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy (2018) (24)
- Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. (2013) (24)
- FDG-PET/CT to Predict Optimal Primary Cytoreductive Surgery in Patients with Advanced Ovarian Cancer: Preliminary Results (2016) (23)
- LASER treatment for women with high‐grade vaginal intraepithelial neoplasia: A propensity‐matched analysis on the efficacy of ablative versus excisional procedures (2018) (23)
- Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin (2015) (23)
- Phase I Study of Gemcitabine and Liposomal Doxorubicin in Relapsed Ovarian Cancer (2002) (23)
- Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study. (2018) (22)
- Neoadjuvant chemotherapy followed by interval debulking surgery for unresectable stage IVB Serous endometrial cancer (2018) (22)
- Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives (2005) (22)
- Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. (2012) (22)
- Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. (2020) (22)
- Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study. (2019) (22)
- Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer (2018) (22)
- The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer (2018) (21)
- A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses (2018) (20)
- Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. (2020) (20)
- Advanced vulvar carcinoma: is it worth operating? A perioperative management protocol for radical and reconstructive surgery. (2006) (20)
- Invasive Paget Disease of the Vulva (2017) (20)
- Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. (2020) (20)
- Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma (2019) (20)
- EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. (2019) (19)
- Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? (2004) (19)
- Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer (2011) (19)
- Newly diagnosed ovarian cancer: Which first-line treatment? (2020) (19)
- Nerve-Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: A Systematic Review and Meta-Analysis. (2017) (19)
- Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. (2013) (18)
- ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer (2021) (18)
- Introducing nerve-sparing approach during minimally invasive radical hysterectomy for locally-advanced cervical cancer: A multi-institutional experience. (2017) (18)
- Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. (2017) (18)
- Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. (2019) (18)
- The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC–IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study (2017) (18)
- Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). (2018) (18)
- Unusual liver locations of growing teratoma syndrome in ovarian malignant germ cell tumors. (2011) (17)
- Evaluating the incidence of pathological complete response in current international rectal cancer practice: the barriers to widespread safe deferral of surgery (2018) (17)
- Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors (2013) (17)
- The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. (2019) (17)
- Sentinel-lymph-node mapping in endometrial cancer. (2017) (17)
- Successful Pregnancy in Stage IE Primary Non-Hodgkin’s Lymphoma of Uterine Cervix Treated with Neoadjuvant Chemotherapy and Conservative Surgery (2008) (17)
- Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma (2014) (17)
- Retrospective study of the influence of HPV persistence on outcomes among women with high‐risk HPV infections and negative cytology (2017) (17)
- Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. (2017) (17)
- Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary (2014) (16)
- Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). (2021) (16)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. (2012) (16)
- Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? (2020) (15)
- Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. (2022) (15)
- Prolonged Chemoradiation in Locally Advanced Carcinoma of the Uterine Cervix: Final Results of a Phase II Study (ESTER-1) (2010) (15)
- Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors (2021) (15)
- Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. (2018) (15)
- Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety (2019) (15)
- A critical assessment on the role of sentinel node mapping in endometrial cancer (2015) (15)
- Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis (2015) (15)
- Angiographic Power 3‐Dimensional Quantitative Analysis in Gynecologic Solid Tumors (2004) (15)
- How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy? (2015) (15)
- Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery (2016) (14)
- The impact of conversion on the risk of major complication following laparoscopic colonic surgery: an international, multicentre prospective audit (2018) (14)
- Celecoxib Up-Regulates the Expression of the ζ Chain of T Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Human Cervical Cancer (2006) (14)
- 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775) (2021) (14)
- The association of pre-treatment HPV subtypes with recurrence of VIN. (2017) (14)
- Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data (2021) (14)
- Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. (2006) (14)
- A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (2021) (14)
- Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC (2016) (14)
- Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. (2017) (14)
- The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study. (2017) (14)
- Nomogram-based prediction of cervical dysplasia persistence/recurrence. (2019) (14)
- When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer (2015) (13)
- Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study) (2019) (13)
- Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers (2017) (13)
- Class II versus Class III radical hysterectomy in early cervical cancer: an observational study in a tertiary center. (2014) (13)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (13)
- LBA40_PRARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC) (2017) (13)
- Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study (2021) (13)
- Advances in laparoscopic surgery for cervical cancer. (2019) (12)
- Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial (2021) (12)
- Pharmacotherapy of cervical cancer (2010) (12)
- PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. (2021) (12)
- Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis (2019) (12)
- Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy (2021) (12)
- Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). (2020) (12)
- The Role of Artificial Intelligence in Managing Multimorbidity and Cancer (2021) (12)
- The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience (2013) (12)
- Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. (2017) (12)
- Lethal Clostridium difficile Colitis Associated with Paclitaxel and Carboplatin Chemotherapy in Ovarian Carcinoma: Case Report and Review of the Literature (2010) (12)
- Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach (2019) (12)
- Incorporating 3D Laparoscopy for the Management of Locally Advanced Cervical Cancer: A Comparison with Open Surgery (2016) (11)
- LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study (2020) (11)
- Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies (2017) (11)
- ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. (2020) (11)
- Treatment modalities for recurrent high-grade vaginal intraepithelial neoplasia (2018) (11)
- 1st Evidence-based Italian Consensus Conference on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Ovarian Cancer (2017) (11)
- Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study. (2022) (11)
- 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study (2021) (11)
- Oncologic effectiveness of nerve-sparing radical hysterectomy in cervical cancer (2018) (11)
- Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. (2016) (11)
- gynaecological cancersA randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) (2016) (10)
- Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer (2020) (10)
- PARP Inhibitors Resistance: Mechanisms and Perspectives (2022) (10)
- Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors (2019) (10)
- RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy. (2019) (10)
- Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine (2021) (10)
- Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance (2020) (10)
- Role of Pegylated Liposomal Doxorubicin (PLD) in Epithelial Ovarian Cancer (2004) (9)
- Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205. (2022) (9)
- Surveillance policy for stage IA malignant ovarian germ cell tumors in children and young adults. (2014) (9)
- Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34) (2020) (9)
- Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: a predictors- and nomogram-based analyses. (2017) (9)
- Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. (2017) (9)
- The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma (2020) (9)
- MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC). (2014) (9)
- Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. (2021) (9)
- The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer (2017) (9)
- Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives. (2020) (9)
- Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer (2019) (9)
- Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV) (2020) (9)
- 518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation (2022) (9)
- Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile (2020) (9)
- Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. (2020) (9)
- Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies (2022) (9)
- Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer (2022) (9)
- The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. (2022) (9)
- Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma: A Retrospective Cohort Study (2014) (9)
- Pneumoperitoneum pressures during pelvic laparoscopic surgery: a systematic review and meta-analysis. (2015) (9)
- Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas (2017) (9)
- Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis. (2005) (8)
- 3D Vision Improves Outcomes in Early Cervical Cancer Treated with Laparoscopic Type B Radical Hysterectomy and Pelvic Lymphadenectomy (2017) (8)
- Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer (2018) (8)
- A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy (2011) (8)
- Peritoneal cytology as prognostic factor in cervical cancer (2015) (8)
- High-Risk Borderline Ovarian Tumors: Analysis of Clinicopathological Features and Prognostic Impact of Different Follow-Up Strategies (2014) (8)
- CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer. (2016) (8)
- Ovarian cancer treatment in mutation carriers/BRCAness. (2016) (8)
- Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors (2010) (8)
- 721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study (2021) (7)
- What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. (2017) (7)
- A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC) (2007) (7)
- Rucaparib: a new treatment option for ovarian cancer (2018) (7)
- Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment (2021) (7)
- Involvement of AF1q/MLLT11 in the progression of ovarian cancer (2017) (7)
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2021) (7)
- Gemcitabine is ineffective in recurrent, preirradiated cervical cancer. (2000) (7)
- Potential impact of introducing a nonavalent HPV vaccination (2018) (7)
- The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy (2022) (7)
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma. (2022) (7)
- Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. (2021) (7)
- The addition of lymphadenectomy to secondary cytoreductive surgery in comparison with bulky node resection in patients with recurrent ovarian cancer (2018) (7)
- Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). (2021) (7)
- Is Postoperative Computed Tomography Evaluation a Prognostic Indicator in Patients with Optimally Debulked Advanced Ovarian Cancer? (2014) (7)
- Sonographic imaging of urinoma (2009) (7)
- Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features (2017) (6)
- A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial). (2014) (6)
- 933PDThe exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: Results from the ENGOT-OV16/NOVA Trial (2017) (6)
- Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial. (2020) (6)
- Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives (2021) (6)
- Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial (2022) (6)
- Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM) (2020) (6)
- Treatment of Recurrent Endometrial Carcinoma: Progress Toward a More Personalized Approach. (2015) (6)
- LBA27PHASE 2 STUDY OF SECOND-LINE DOVITINIB (TKI258) IN PATIENTS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)-MUTATED OR -NONMUTATED ADVANCED AND/OR METASTATIC ENDOMETRIAL CANCER (2014) (6)
- Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer (2019) (6)
- Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis (2022) (5)
- Immunotherapy and epithelial ovarian cancer: a double-edged sword? (2017) (5)
- Investigational agents against platinum-resistant ovarian cancer (2007) (5)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4) (2022) (5)
- ENGOT-OV16/NOVA: A Maintenance sturdy with Niraparib versus placebo in patients with platinum-sensitive ovarian cancer (2016) (5)
- 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (2022) (5)
- Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration (2018) (5)
- Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio (2016) (5)
- Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases. (2020) (5)
- Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC). (2021) (5)
- Role of bevacizumab in uterine leiomyosarcoma. (2018) (5)
- 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety (2022) (5)
- Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence. (2016) (5)
- Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. (2019) (5)
- Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC). (2010) (4)
- Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings (2019) (4)
- How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review (2022) (4)
- Sentinel lymph node detection in endometrial cancer: does injection site make a difference? (2015) (4)
- Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Preliminary activity results of the MITO-2 randomized multicenter trial (2007) (4)
- Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse. (2018) (4)
- Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years (2022) (4)
- A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. (2016) (4)
- Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. (2019) (4)
- Expression III: What do primary and recurrent ovarian cancer (OC) patients expect from their doctors and therapy management? Results of a survey in eight European countries with 1,743 patients (NOGGO/ENGOT-OV9 study). (2013) (4)
- 519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis (2022) (4)
- Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC–IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study (2018) (4)
- Phase II exploratory study of brostallicin in patients with ovarian cancer resistant/refractory to platinum-based chemotherapy (2008) (4)
- 524MO Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel (2022) (4)
- Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel (2020) (4)
- Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors (2022) (4)
- Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer). (2019) (4)
- Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? (2022) (4)
- Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer. (2017) (4)
- Reply to A Buda (2016) (4)
- Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial (2023) (4)
- 941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER. (2014) (4)
- Abstract LB-A12: Results from the phase 3 study ARIEL3: mutations in non-BRCA homologous recombination repair genes confer sensitivity to maintenance treatment with the PARP inhibitor rucaparib in patients with recurrent platinum-sensitive high-grade ovarian carcinoma (2018) (4)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3 (2021) (4)
- Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study (2021) (3)
- Validation of the geriatric vulnerability score (GVS) in older ovarian cancer (oOC) patients: An analysis from the GCIG-ENGOT-GINECO EWOC-1 study (2019) (3)
- Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. (2014) (3)
- Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. (2011) (3)
- Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital (2021) (3)
- O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (2022) (3)
- 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? (2022) (3)
- 738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial (2021) (3)
- Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience. (2015) (3)
- Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. (2019) (3)
- Il cancro sul grande schermo. Quanto, come e quando il cinema si occupa delle malattie oncologiche (2014) (3)
- Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer (2004) (3)
- Bulky Mesonephric Adenocarcinoma of the Uterine Cervix Treated with Neoadjuvant Chemotherapy and Radical Surgery: Report of the First Case (2016) (3)
- Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab (2019) (3)
- Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study. (2018) (3)
- Oncomovies: Cancer in Cinema (2012) (3)
- PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer. (2014) (3)
- Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3. (2018) (3)
- Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. (2015) (3)
- Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report. (2016) (3)
- Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy (2019) (3)
- BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories (2019) (3)
- O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma (2021) (3)
- Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024). (2020) (3)
- Long-term safety assessment of niraparib in patients with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial (2019) (3)
- Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety (2021) (3)
- Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study (2019) (3)
- Investigating the Role of Minimally Invasive Radical Hysterectomy in Cervical Cancer (2018) (3)
- Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: a literature review. (2021) (3)
- Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study (2023) (3)
- A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group (2022) (3)
- Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC). (2022) (3)
- Oregovomab: an investigational agent for the treatment of advanced ovarian cancer (2021) (3)
- Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8) (2019) (3)
- 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study (2020) (3)
- Recent progress in the use of pharmacotherapy for endometrial cancer (2022) (2)
- Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients (2022) (2)
- ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma. (2017) (2)
- Multicenter retrospective analysis of 31 patients with aggressive angiomyxoma. (2014) (2)
- Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study (2021) (2)
- Phase II study on pemetrexed in advanced and/or recurrent cervical cancer patients: a MITO study (2008) (2)
- A randomized phase II study assessing an optimized schedule of oregovomab (O) anti-CA125 vaccination with carboplatin paclitaxel (CP) relative to CP alone in front-line treatment of optimally cytoreduced stage III/IV ovarian cancer (EOC). (2017) (2)
- D01*MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer (2015) (2)
- Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3 (2020) (2)
- Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) (2022) (2)
- 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011) (2022) (2)
- Integration of PARP-inhibitors in ovarian cancer therapy (2020) (2)
- Regional differences in therapy and clinical management of endometrial cancer: Findings of an international survey by the North-eastern German Society of Gynaecological Oncology (NOGGO). (2013) (2)
- O013/#573 Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results (2021) (2)
- Chemotherapy-free treatments: are we ready for prime time? (2019) (2)
- Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on use of trabectedin. (2020) (2)
- Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis (2022) (2)
- [Cancer on the big screen. How and when movies deal with oncological diseases]. (2014) (2)
- Predicting Factors for High-Grade Cervical Dysplasia in Women With Low-Grade Cervical Cytology and Nonvisible Squamocolumnar Junction (2019) (2)
- Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study (2019) (2)
- Locally Advanced Cervical Cancer: Is a Trimodality Treatment a Safe and Effective Approach? (2018) (2)
- A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLD) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group. (2006) (2)
- Capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study (2019) (2)
- 527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study (2022) (2)
- The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma (2019) (2)
- EPIK-O/ENGOT-OV61: Alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). (2022) (2)
- Discussion: session 2. (2013) (2)
- Discussion: session 1. (2013) (2)
- Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase III study ARIEL3 of rucaparib maintenance treatment (2019) (2)
- Corrigendum to "Advances in laparoscopic surgery for cervical cancer" [Crit. Rev. Oncol. Hematol. 143 (August) (2019) 76-80]. (2019) (2)
- High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy (2013) (2)
- [Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.] (2017) (2)
- Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project (2017) (2)
- Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC) (2018) (2)
- Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma. (2005) (2)
- Phase II Study on Weekly Bolus Topotecan in Advanced or Recurrent Cervical Cancer (2011) (2)
- Endometrial carcinosarcoma (2022) (2)
- The role of niraparib in the treatment of ovarian cancer: actuality and perspectives (2017) (2)
- Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer (2020) (2)
- Bevacizumab treatment and quality of life in advanced ovarian cancer. (2013) (2)
- Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey (2022) (2)
- Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer. (2004) (2)
- 199 Randomised Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer (2021) (2)
- 1 Analysis of patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer in the phase 3 ARIEL3 study (2021) (1)
- The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (2018) (1)
- EP233/#541 Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-ov26/GOG-3012 post-hoc subgroup analysis (2022) (1)
- 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations (2020) (1)
- Chemotherapy-free treatments: are we ready for prime time? (2019) (1)
- EPV279/#351 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline brca mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2021) (1)
- Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer (2023) (1)
- Prognostic factors in granulosa cell tumors (GCT) . A MITO-9 retrospective study (2011) (1)
- MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis. (2022) (1)
- First line ovarian cancer treatment: scanning the horizon. (2021) (1)
- MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trial—A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer. (2015) (1)
- LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study (2021) (1)
- Is chemotherapy worthwhile in patients with high-risk, lymph node negative, FIGO stage 1, endometrial cancer? (2017) (1)
- Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26). (2022) (1)
- 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2021) (1)
- 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775 (2022) (1)
- Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study. (2022) (1)
- 956 Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: results from the POD1UM-101 study (2021) (1)
- Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. (2023) (1)
- NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC). (2012) (1)
- 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (1)
- Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer (ROC) patients. (2011) (1)
- Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives (2021) (1)
- ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* (2023) (1)
- O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study (2022) (1)
- OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. (2015) (1)
- A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer. (2018) (1)
- The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma (2018) (1)
- PCN295 PATIENT-CENTERED OUTCOMES IN ARIEL3, A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH RECURRENT OVARIAN CARCINOMA (2019) (1)
- Oncology and public health (2012) (1)
- Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. (2021) (1)
- Ovarian preservation in locally advanced cervical cancer undergoing neoadjuvant chemotherapy and radical surgery. (2018) (1)
- NGR-hTNf plus doxorubicin in recurrent ovarian cancer (2012) (1)
- TP004/#1457 Trial in progress of engot-CX8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer (2022) (1)
- Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis (2022) (1)
- 536P Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: Phase II subgroup analysis mirroring the patient population of an upcoming phase III study (2022) (1)
- 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine (2022) (1)
- 886PDTRABECTEDIN IN PATIENTS WITH BRCA MUTATED AND BRCANESS PHENOTYPE ADVANCED OVARIAN CANCER (AOC): PHASE II PROSPECTIVE MITO-15 STUDY. (2014) (1)
- 366 Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer (2020) (1)
- Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial (2021) (1)
- 988TiPARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer (2017) (1)
- Gemcitabine (GEM) and liposomal doxorubicin (PLD) in recurrent/metastatic breast carcinoma: A phase II study (2005) (1)
- Expression III: Final results of an international survey in eight European countries with 1,830 patients—What are the differences in expectations from their doctors and therapy management of patients with primary and recurrent ovarian cancer? (NOGGO/ENGOT-ov4 study). (2014) (1)
- 715 POSTER Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors (2007) (1)
- Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women. (2016) (1)
- 45TiP A randomized, molecular driven phase II trial of carboplatin-paclitaxel-bev vs carboplatin-paclitaxel-bev-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer (2022) (1)
- 20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC) (2022) (1)
- Tailoring adjuvant treatment in patients with uterine cancer. (2018) (1)
- 33O PRIMA/ENGOT-OV26/GOG-3012 study: Long-term conditional PFS (2023) (1)
- Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC). (2011) (1)
- Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC). (2014) (1)
- 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775) (2021) (1)
- Phase II study on the combination carboplatin-celecoxib in heavily pre-treated recurrent ovarian carcinoma patients. (2006) (1)
- Safety and effectiveness of Human Papillomavirus (HPV) vaccination: NCI of Milan position statement. (2017) (1)
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer (2022) (1)
- 2022-RA-944-ESGO Real-world safety, baseline characteristics and first-year therapy management in patients withBRCA1/BRCA2-mutated advanced ovarian cancer treated with olaparib tablets in the first-line maintenance setting: first analysis of the pan-European OVAL-1 study (2022) (1)
- PARPi related toxicities: do we need more appropriate instruments to evaluate it? (2018) (1)
- Dostarlimab: From preclinical investigation to drug approval and future directions (2023) (1)
- Corrigendum to "Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia)" [Eur J Canc. vol. 139 November (2020) Pages 149-168]. (2020) (1)
- 2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma (2019) (1)
- Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): Results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial. (2015) (1)
- A common pattern of somatic mutations in t‐MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer (2022) (1)
- Integrating antibody drug conjugates in the management of gynecologic cancers (2023) (1)
- 592P Exposure response (ER) analysis for efficacy and safety of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer (2022) (1)
- O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors (2021) (1)
- Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center (2022) (1)
- Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer (2022) (1)
- Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives (2022) (1)
- EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress) (2021) (1)
- Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial. (2017) (1)
- 525MO Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775 (2022) (1)
- Survival With Cemiplimab in Recurrent Cervical Cancer (2022) (0)
- Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3. (2018) (0)
- Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775. (2022) (0)
- Contents Vol. 75, 2008 (2008) (0)
- Vulvar and Vaginal Cancers (2021) (0)
- A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma (2018) (0)
- Tisotumab vedotin in recurrent or metastatic cervical cancer. (2023) (0)
- G04Quality of life (QOL) analysis of the MITO8 phase 3 trial, a collaboration of MITO, Mango, AGO Study Group, BGOG, ENGOT, and GCIG (2016) (0)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer (2023) (0)
- 42P Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation (2023) (0)
- Ngr-htnf plus doxorubicin in relapsed ovarian carcinoma (2013) (0)
- Phase II study of the safety and efficacy of oral capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma. (2017) (0)
- Bevacizumab treatment & quality of life in advanced ovarian cancer Priority Paper Evaluation (2010) (0)
- Assessing the Risk of Pelvic and Para-Aortic Nodal Involvement in Apparent Early-Stage Ovarian Cancer Undergoing Retroperitoneal Staging (2017) (0)
- Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. (2023) (0)
- COVID-19 pandemic in Italy: Social distress and gender imbalance among health care professionals (2020) (0)
- EFFECT OF PRIOR BEVACIZUMAB THERAPY IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (ROC) IN THE PHASE 3 STUDY ARIEL3 (2018) (0)
- Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors (2023) (0)
- Efficacy and safety outcomes in heavily pretreated patients (pts) with relapsed ovarian cancer (ROC) after single-agent trabectedin. (2013) (0)
- Abstract CT046: A randomized, phase 2 study of pembrolizumab plus chemotherapy with or without anti—immunoglobulin-like transcript 4 monoclonal antibody MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer (2023) (0)
- Guidelines in ovarian cancer (2012) (0)
- The impact of chemotherapy-related leukopenia on survival outcomes in locally advanced cervical cancer. (2017) (0)
- Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study of the IRCCS National Cancer Institute of Milan (2016) (0)
- Trabectidin as single-agent in heavily pretreated patients with relapsed ovarian cancer (ROC): results from a retrospective study (2013) (0)
- Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine (2021) (0)
- OP14.09: Ultrasound‐guided radiolocalisation of inguinal lymph nodes in selected patients with gynecological cancers: a pilot study (2016) (0)
- Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer (2016) (0)
- Phase Ib/II trial of tisotumab vedotin+/- bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024) (2020) (0)
- 419 - Incorporating Minimally Invasive Nerve-Sparing Radical Hysterectomy for Locally-Advanced Cervical Cancer (2017) (0)
- 31P Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors (2022) (0)
- 180 Real-world treatment patterns and outcomes with first-line maintenance olaparib for BRCAm advanced ovarian cancer: a pan-European study (OVAL-1) (2021) (0)
- 1845P Features of clinical trials leading to oncologic drugs approval in europe (2021) (0)
- Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. (2023) (0)
- Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives. (2021) (0)
- Ovarian Cancer, Early Primary Disease (2021) (0)
- 58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer (2021) (0)
- 8030 Prospective validation of a predictive score for complete tumor resection in recurrent ovarian cancer (ROC): an intergroup study of AGO kommission OVAR, AGO-OVAR, AGO Austria, MITO and NOGGO (2009) (0)
- Doppler evaluation in gynecological tumor recurrences (2001) (0)
- Progression-Free Survival and Safety at 3.5 Years of Follow-Up: Results From the Randomized Phase 3 PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (2023) (0)
- Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3 (2019) (0)
- 52P Real-world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group (2023) (0)
- 50P Direct-acting oral anticoagulants prescribing pattern in patients with gynaecological cancer: Results of a survey among Italian oncologists belonging to MITO group and AIOM society (2022) (0)
- Retraction Statement. Paper by Manizate et al., entitled ‘Liver functional reserve estimation: state of the art and relevance to local treatments‘ Oncology 2010;78(suppl 1):131-134, DOI: 10.1159/000315241 (2014) (0)
- ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023. (2023) (0)
- EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum- (2019) (0)
- 12P Tisotumab vedotin in recurrent or metastatic cervical cancer (2023) (0)
- 2022-RA-1294-ESGO Chemosensitivity in vulnerable older patients is unfavorable and highly dependent on the treatment regimen: CA125 elimination rate constant K (KELIM) analysis of the GINECO-ENGOT EWOC-1 trial (2022) (0)
- Human Cervical Cancer Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Chain of T ζ Celecoxib UpRegulates the Expression of the Updated version (2006) (0)
- Single Arm Phase II Study on Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions (2019) (0)
- OC07.05: Application of 3D ultrasound in the assessment of dose-dense NACT efficacy in patients with cervical cancer (2015) (0)
- CLINICAL OUTCOME OF SECONDARY SURGERY IN RECURRENT ENDOMETRIAL CANCER (2014) (0)
- HEPATIC SURGERY DURING CYTOREDUCTION FOR PRIMARY OR RECURRENT OVARIAN CANCER (2014) (0)
- Ovarian Cancer: Primary Advanced and Recurrent Disease (2021) (0)
- 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22 (2022) (0)
- TP003/#1533 MITO CERV3_phase II study on carboplatin-paclitaxel-pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer (2022) (0)
- Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline? (2023) (0)
- The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma. (2022) (0)
- Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice. (2023) (0)
- Laparoscopic Mapping in Endometrial Cancer Following Hysteroscopic Injection of Indocyanine Green (2016) (0)
- Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer. (2006) (0)
- Title: Chemotherapy-Related Leukopenia as a Biomarker Predicting Survival Outcomes in Locally Advanced Cervical Cancer Running title: Chemotherapy-related immunosuppression and survival outcomes (2016) (0)
- A Prospective Study on the Risk of Occult Malignancies and 30-Day Morbidity in Women Undergoing Miniamlly Invasive Risk-Reducing Surgery (2017) (0)
- Evaluation of capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: A retrospective study of the IRCCS National Cancer Institute of Milan. (2018) (0)
- Management of Rare Uterine Malignant Tumors (2019) (0)
- 2022-RA-1214-ESGO Best option treatment in first line setting for low grade serous ovarian cancer:a case-control study (2022) (0)
- D02Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial (2015) (0)
- Sensitivity to chemotherapy of low-grade endometrial stromal sarcoma (LGESS) versus high-grade endometrial stromal sarcoma (HGESS). (2017) (0)
- 164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy (2021) (0)
- TP017/#1455 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204) (2022) (0)
- Chemotherapy in Endometrial Cancer (2019) (0)
- TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33) (2022) (0)
- Immunotherapy in gynecological cancers (2021) (0)
- Advanced and recurrent endometrial cancer: state of the art and future perspectives. (2022) (0)
- Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study (2005) (0)
- Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors (2023) (0)
- 40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer (2021) (0)
- 150 - Oncologic Effectiveness and Safety of Nerve-Sparing Radical Hysterectomy in Cervical Cancer (2017) (0)
- Findings Linking Mismatch Repair Mutation With Age at Endometrial and Ovarian Cancer Onset in Lynch Syndrome. (2018) (0)
- CELECOXIB, A SELECTIVE CYCLOOXYGENASE-2 (COX-2) INHIBITOR, MODULATES CYTOKINES LEVELS IN SERUM OF CERVICAL CANCER PATIENTS (2004) (0)
- Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]. (2022) (0)
- EPV036/#142 European network for gynaecological oncological trial (ENGOT)-CX11/gynecologic oncology group (GOG) 3047/keynote-A18: phase 3 trial of pembrolizumab plus chemoradiotherapy in high-risk locally advanced cervical cancer (2021) (0)
- Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study (2019) (0)
- Impact of Morcellation of Occult Malignancies at the Time of Vaginal Hysterectomy. (2017) (0)
- 977PIs chemotherapy worthwhile in patients with FIGO stage 1B, lymph nodes negative, grade 3 endometrial cancer? (2017) (0)
- A UTERINE-CONFINED PHASE 3 STUDY OF PEMBROLIZUMAB OR PLACEBO IN COMBINATION WITH ADJUVANT CHEMOTHERAPY WITH/WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK (2022) (0)
- Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial (2022) (0)
- A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer (2020) (0)
- Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma (2022) (0)
- EPV106/#249 Endometrial cancer immunohistochemical risk stratification in a large uterine-confined cancer series (2021) (0)
- Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress). (2021) (0)
- ARIEL4: An international, randomised phase 3 study of rucaparib vs chemotherapy as treatment for BRCA1- or BRCA2-mutated, relapsed ovarian cancer. (2017) (0)
- 2022-LBA-746-ESGO Implementation of a comprehensive cancer genome profiling programme into clinical practice: an italian experience in a referral centre for gynecological cancers (2022) (0)
- Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review (2022) (0)
- 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (2022) (0)
- 27P Clinical relevance of NGS analysis in endometrial cancer (EC) management (2022) (0)
- 152 - Sentinel Node Detection in Endometrial Cancer: A Single Center Experience Over 200 Cases of Hysteroscopic Injection of Tracers (2017) (0)
- Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy". (2017) (0)
- Benign metastasizing leiomyoma (BML): A retrospective case series analysis of 8 patients (pts). (2017) (0)
- Uterine leiomyosarcoma diagnosis 5 years after high-intensity focused ultrasound treatment under magnetic resonance guidance for fibroid. (2021) (0)
- 0244: A Phase II Study of Two Different Induction Regimens of High Dose Carboplatin (Hdc) Vs Weekly Paclitaxel/Gemcitabine (Wpg) Followed By Pacli-Taxel/Carboplatin/Gemcitabine (Pcg) in Advanced Ovarian Cancer (Aoc) (2006) (0)
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC). (2021) (0)
- Phase II trial on cisplatin-doxorubicin hydrochloride-paclitaxel (TAP) combination as neoadjuvant chemotherapy (NACT) for locally advanced cervical adenocarcinoma (LACA). (2017) (0)
- O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775 (2022) (0)
- PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. (2023) (0)
- EP264/#556 Physician-reported patient involvement in 1l ovarian cancer treatment, including maintenance, in the US and Europe: a real-world chart review analysis (2017–2020) (2022) (0)
- Dose dense neoadjuvant chemotherapy (NACT) with carboplatin-paclitaxel in locally advanced cervical cancer. (2018) (0)
- P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC) (2019) (0)
- Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. (2023) (0)
- Neoadjuvant chemotherapy-related leukopoenia as a biomarkers predicting survival outcomes in locally advanced cervical cancer (2018) (0)
- 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205 (2022) (0)
- The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer (216) (2022) (0)
- Treatment of Early Ovarian Cancer (2015) (0)
- The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors. (2018) (0)
- Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer (2022) (0)
- 2022-LBA-677-ESGO Distribution and prognostic role of BRCA status in elderly ovarian cancer patients (2022) (0)
- 32O 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial (2023) (0)
- The role of laparoscopy in evaluating cytoreduction in advanced ovarian cancer (2017) (0)
- Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. (2023) (0)
- TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer (2022) (0)
- Analisi di minimizzazione dei costi di una strategia di test preventivo per le familiari di pazienti con carcinoma dell’ovaio BRCA mutato (2020) (0)
- Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial. (2023) (0)
- 16/#430 Phase 2 results of relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer with and without prior bevacizumab (2022) (0)
- [Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] (2021) (0)
- An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer (2022) (0)
- EP064/#192 Potential mechanism for ocular adverse events observed with tisotumab vedotin (2022) (0)
- P31.03: Tumor volume as risk factor for nodal diffusion in endometrial cancer (2014) (0)
- Contents Vol. 80, 2011 (2011) (0)
- 132P Genomic profiling of primary and recurrent ovarian cancers: A retrospective single-center experience (2022) (0)
- Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience (2023) (0)
- NELLA SPIRALE DEL CLIMA culture e società mediterranee di fronte ai cambiamenti climatici (2010) (0)
- Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age (2019) (0)
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (2022) (0)
- Endometrial and Cervical Cancers (2021) (0)
- 164 ENGOT-cx11/GOG 3047/KEYNOTE-A18: a phase 3, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer (2020) (0)
- Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial (2023) (0)
- Diagnosis of uterine leiomyosarcoma 5 years after magnetic‐resonance‐guided high‐intensity focused ultrasound treatment of fibroid (2022) (0)
- Subject Index Vol. 75, 2008 (2008) (0)
- A loss of microRNA expression as a characterization of synchronous peritoneal secondary localizations of epithelial ovarian cancer as compared to primary tumors. (2013) (0)
- 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito (2022) (0)
- TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer (2022) (0)
- Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023) (2022) (0)
- Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative (2022) (0)
- 2022-RA-1414-ESGO Pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with Niraparib (2022) (0)
- How is the current clinical management of endometrial cancer worldwide? An international survey by the North-Eastern German Society of Gynaecological Oncology (NOGGO). (2012) (0)
- Quality-adjusted time without symptom or toxicity and quality-adjusted progression-free survival of first-line maintenance niraparib in patients with advanced ovarian cancer (2021) (0)
- Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy (2010) (0)
- 86 Endometrial Cancer Immunohistochemical Risk Stratification in a large uterine-confined cancer series (2021) (0)
- 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer (2021) (0)
- Management of stage III and IVa uterine cancer (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Domenica Lorusso?
Domenica Lorusso is affiliated with the following schools:
